{
    "id": 27305,
    "fullName": "EGFR L747_A750delinsP",
    "impact": "indel",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "EGFR L747_A750delinsP results in a deletion of four amino acids in the protein kinase domain of the Egfr protein from aa 746 to aa 750, combined with the insertion of a proline (P) at the same site (UniProt.org). L747_A750delinsP results in increased transformation ability in two different cell lines in one study (PMID: 29533785) and therefore, is predicted to lead to a gain of Egfr protein function.",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 11238,
                    "pubMedId": 29533785,
                    "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 1956,
        "geneSymbol": "EGFR",
        "terms": [
            "EGFR",
            "ERBB",
            "ERBB1",
            "HER1",
            "mENA",
            "NISBD2",
            "PIG61"
        ]
    },
    "variant": "L747_A750delinsP",
    "createDate": "11/28/2017",
    "updateDate": "09/11/2018",
    "referenceTranscriptCoordinates": {
        "id": 135749,
        "transcript": "NM_005228",
        "gDna": "chr7:g.55174776_55174787delinsCCT",
        "cDna": "c.2239_2250delinsCCT",
        "protein": "p.L747_A750delinsP",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 19133,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, EGFR L747_A750delinsP was associated with shorter median progression-free survival (4.1 months vs 11.4 months), shorter treatment duration (5.9 vs 14.8 months), and shorter median overall survival (14.1 months vs 47.0 months) compared to other EGFR exon 19 deletions in an analysis of 32 non-small cell lung cancer patients treated with Tarceva (erlotinib), and 2 of the 4 patients harboring EGFR L747_A750delinsP had demonstrated primary resistance to Tarceva (erlotinib) (PMID: 31182434).",
            "molecularProfile": {
                "id": 28728,
                "profileName": "EGFR L747_A750delinsP"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 16743,
                    "pubMedId": 31182434,
                    "title": "The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31182434"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19131,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an established lung adenocarcinoma cell line harboring EGFR L747_A750delinsP demonstrated increased sensitivity to Gilotrif (afatinib) compared to other EGFR inhibitors and to cell lines harboring another exon 19 deletion, and Gilotrif (afatinib) was more effective in inhibiting EGFR phosphorylation and cell viability in a lung adenocarcinoma patient-derived cell line harboring EGFR L747_A750delinsP compared to other EGFR inhibitors, in culture (PMID: 31182434).",
            "molecularProfile": {
                "id": 28728,
                "profileName": "EGFR L747_A750delinsP"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16743,
                    "pubMedId": 31182434,
                    "title": "The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31182434"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19865,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Gilotrif (afatinib) treatment resulted in a partial response in one primary tumor site and complete response in other sites in a patient with lung adenocarcinoma harboring EGFR L747_A750delinsP, with a progression-free survival of 48 months (PMID: 31941684).",
            "molecularProfile": {
                "id": 28728,
                "profileName": "EGFR L747_A750delinsP"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17556,
                    "pubMedId": 31941684,
                    "title": "The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma-Letter.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31941684"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12516,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR L747_A750delinsP were sensitive to treatment with Tarceva (erlotinib) in culture, demonstrating reduced cell viability (PMID: 29141884).",
            "molecularProfile": {
                "id": 28728,
                "profileName": "EGFR L747_A750delinsP"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10358,
                    "pubMedId": 29141884,
                    "title": "A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29141884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12521,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR L747_A750delinsP were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).",
            "molecularProfile": {
                "id": 28728,
                "profileName": "EGFR L747_A750delinsP"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10358,
                    "pubMedId": 29141884,
                    "title": "A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29141884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12519,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR L747_A750delinsP were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).",
            "molecularProfile": {
                "id": 28728,
                "profileName": "EGFR L747_A750delinsP"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10358,
                    "pubMedId": 29141884,
                    "title": "A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29141884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19120,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a lung adenocarcinoma patient harboring EGFR L747_A750delinsP did not achieve a durable response to Tarceva (erlotinib), and in a cell line derived from the patient's tumor, Tarceva (erlotinib) did not fully inhibit EGFR phosphorylation and demonstrated a reduced impact on viability compared to a cell line harboring another exon 19 deletion (PMID: 31182434).",
            "molecularProfile": {
                "id": 28728,
                "profileName": "EGFR L747_A750delinsP"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 16743,
                    "pubMedId": 31182434,
                    "title": "The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31182434"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19866,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Tarceva (erlotinib) treatment resulted in a partial response initially in a patient with lung adenocarcinoma harboring EGFR L747_A750delinsP, but the disease progressed after 8 months (PMID: 31941684).",
            "molecularProfile": {
                "id": 28728,
                "profileName": "EGFR L747_A750delinsP"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 17556,
                    "pubMedId": 31941684,
                    "title": "The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma-Letter.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31941684"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12520,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR L747_A750delinsP were sensitive to treatment with Rociletinib (CO-1686) in culture, demonstrating reduced cell viability (PMID: 29141884).",
            "molecularProfile": {
                "id": 28728,
                "profileName": "EGFR L747_A750delinsP"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10358,
                    "pubMedId": 29141884,
                    "title": "A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29141884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19132,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an established lung adenocarcinoma cell line harboring EGFR L747_A750delinsP demonstrated decreased sensitivity to Tagrisso (osimertinib) compared to Gilotrif (afatinib) and to cell lines harboring another exon 19 deletion, and a lung adenocarcinoma patient-derived cell line harboring EGFR L747_A750delinsP demonstrated decreased sensitivity to inhibition of EGFR phosphorylation and cell viability by Tagrisso (osimertinib) compared to Gilotrif (afatinib) in culture (PMID: 31182434).",
            "molecularProfile": {
                "id": 28728,
                "profileName": "EGFR L747_A750delinsP"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 16743,
                    "pubMedId": 31182434,
                    "title": "The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31182434"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12517,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR L747_A750delinsP were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).",
            "molecularProfile": {
                "id": 28728,
                "profileName": "EGFR L747_A750delinsP"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10358,
                    "pubMedId": 29141884,
                    "title": "A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29141884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15135,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a patient with non-small cell lung cancer initially responded to Tarceva (erlotinib), EGFR L747_A750delinsP and FGFR3-TACC3 were identified in post-progression tumor samples (PMID: 29883838).",
            "molecularProfile": {
                "id": 30782,
                "profileName": "FGFR3 - TACC3 EGFR L747_A750delinsP"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 12672,
                    "pubMedId": 29883838,
                    "title": "Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29883838"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16635,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, EGFR T790M was identified in the post-progression lesions from a patient with bronchioloalveolar carcinoma harboring EGFR L747_A750delinsP (reported as EGFR L747_E749del; A750P) with acquired resistance to Tarceva (erlotinib) (PMID: 15737014).",
            "molecularProfile": {
                "id": 34567,
                "profileName": "EGFR L747_A750delinsP EGFR T790M"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 4926,
                "name": "bronchiolo-alveolar adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 1879,
                    "pubMedId": 15737014,
                    "title": "Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15737014"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19867,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Tagrisso (osimertinib) treatment resulted in rapid disease progression in a patient with lung adenocarcinoma harboring EGFR L747_A750delinsP and EGFR T790M, with a progression-free survival of 1.9 months (PMID: 31941684).",
            "molecularProfile": {
                "id": 34567,
                "profileName": "EGFR L747_A750delinsP EGFR T790M"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 17556,
                    "pubMedId": 31941684,
                    "title": "The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma-Letter.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31941684"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 28728,
            "profileName": "EGFR L747_A750delinsP",
            "profileTreatmentApproaches": [
                {
                    "id": 16621,
                    "name": "EGFR Inhibitor (Pan)",
                    "profileName": "EGFR L747_A750delinsP"
                },
                {
                    "id": 16622,
                    "name": "EGFR Inhibitor 1st gen",
                    "profileName": "EGFR L747_A750delinsP"
                },
                {
                    "id": 16624,
                    "name": "EGFR Inhibitor 3rd gen",
                    "profileName": "EGFR L747_A750delinsP"
                },
                {
                    "id": 16625,
                    "name": "HER inhibitor (Pan)",
                    "profileName": "EGFR L747_A750delinsP"
                },
                {
                    "id": 16623,
                    "name": "EGFR Inhibitor 2nd gen",
                    "profileName": "EGFR L747_A750delinsP"
                }
            ]
        },
        {
            "id": 30782,
            "profileName": "FGFR3 - TACC3 EGFR L747_A750delinsP",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34567,
            "profileName": "EGFR L747_A750delinsP EGFR T790M",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 135749,
            "transcript": "NM_005228",
            "gDna": "chr7:g.55174776_55174787delinsCCT",
            "cDna": "c.2239_2250delinsCCT",
            "protein": "p.L747_A750delinsP",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}